25 results
8-K
EX-10.1
ADPT
Adaptive Biotechnologies Corp
12 Sep 22
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
8:45am
or correspondence from any Regulatory Agency, comparable authority, or institutional review board or ethics committee requiring the termination, suspension
424B5
r7nt7llx8vtz0h
16 Jul 20
Prospectus supplement for primary offering
4:26pm
424B5
lkz ed3s5kpmxy
14 Jul 20
Prospectus supplement for primary offering
5:01pm
DEF 14A
op2z03l34ky tw
24 Apr 20
Definitive proxy
4:15pm
10-K
3c5 ml2fy0fww
26 Feb 20
Annual report
4:53pm
424B4
w9d ms023
24 Jan 20
Prospectus supplement with pricing info
4:49pm
DRS
uszhb9hgj06i jjh
9 Jan 20
Draft registration statement
12:00am
424B4
nm5p1 06k5fa01
27 Jun 19
Prospectus supplement with pricing info
5:24pm